Tobacco users are estimated to be at least 1.1 billion worldwide. Although tobacco dependence is not associated with obvious behavioral disruptions, alleviating it is a major public health concern and a main societal challenge, as it produces severe long-lasting health-related problems, leading to 6 million deaths every year. Available therapies for smoking cessation have limited efficacy, warranting the need for developing better therapeutic strategies, which depend on understanding the mechanisms that underlie tobacco dependence, in which nicotine is considered to have a central role.
The relevance of preclinical animal models to nicotine dependence is questioned because their predictive validity is considered poor (Hong et al, 2010). In spite of this, preclinical animal models of nicotine seeking have been proved useful, as they have helped in understanding the mechanisms underlying nicotine seeking. These models, in line with clinical studies, have consistently demonstrated that both pharmacological factors (PF) and non-pharmacological factors (NPF) promote nicotine seeking and have helped identify underlying neurobiological mechanisms (Stoker and Markou, 2015).
Increasing psychological, genetic, and neurobiological data support the notion that the contribution of PF and NPF to nicotine seeking differ from smoker to smoker, thus possibly contributing to the observed heterogeneity in the population of smokers (Hiroi and Scott, 2009). It could also contribute to the incongruence between the multiple diagnosis tools, the inconsistent relationship between craving and smoking cessation outcome, and the limited predictive validity of animal models. This might also eventually reduce our ability to identify relevant therapeutic targets for smoking cessation (Potvin et al, 2015).
For instance, a single-nucleotide polymorphism of the CHRNA5 gene has been associated with heavy smoking, which appears to be caused by a lowered sensitivity to the aversive effects of nicotine (Fowler and Kenny, 2014). In smokers who carry this CHRNA5 risk allele, compared with noncarriers, nicotine seeking through PF is increased, namely through withdrawal avoidance, whereas susceptibility to NPF, in particular cue-induced craving (Janes et al, 2012), is decreased. This supports the notion that the two types of factors (PF/NPF) can vary independently. Fast nicotine metabolism is another risk factor for heavy smoking and low cessation rates (Mamoun et al, 2015). Fast nicotine metabolizers are more sensitive to withdrawal than their slow metabolizer counterparts, but differently from the CHRNA5 case, they are also more responsive to drug cues (Falcone et al, 2016); a difference possibly due to their specific nicotine pharmacodynamics that might favor cue conditioning. Altogether, specific combinations of risk and protective factors, like these and many others, will determine the individual mechanisms underlying nicotine seeking.
We propose that the predictive validity of animal models might increase by taking into account these individual variations. This implies determining, within the same individuals, the influence of both PF and NPF in the control of nicotine seeking, and evaluating how individual psychobiological factors and length of nicotine exposure (early vs late nicotine use) affect this balance (Figure 1).
The exploration of individual differences in nicotine self-administration is at a very early stage. A recent exhaustive review by Falco and Bevins (2015) on individual differences in the behavioral effects of nicotine refers to only four self-administration studies that investigated the relationships between impulsivity-related psychobehavioral traits and nicotine self-administration. However, even this very limited body of research has produced inconsistent results and has yet to identify underlying mechanisms of nicotine seeking.
Now important conditions are met for investigating individual variations in nicotine seeking. Over the last 15 years, tremendous progress has been made in modeling nicotine taking in rodents using intravenous self-administration. Newer developments include the exploration of alternative routes of administration (Cohen and George, 2013) or even self-administration (www.simply-lab.com) (ie, vapor inhalation), as well as the influence of social factors on nicotine taking (Wang et al, 2014). Thanks to these models, key information has been collected on the control of nicotine seeking by PF and notably NPF, thanks to the seminal work of Anthony Caggiula and Eric Donny (Pittsburgh University, USA) on the complex control of nicotine seeking by conditioned factors. Also significant, investigating the mechanisms by which nicotine alters contextual learning, Thomas J Gould and colleagues (Temple University, Philadelphia, USA) have contributed to the current view on how nicotine withdrawal might promote seeking through cognitive impairments and negative affective state.
Over the same time period, new mouse genetic models have been developed to reproduce human allelic variations in nAChR subtypes associated with increased risk for nicotine dependence (Morel et al, 2014). Furthermore, newer experimental tools, such as opto- and chemogenetics, viral tracing techniques, and brain calcium imaging in freely behaving rodents allow for precise investigations of neural circuit function, including those relevant to nicotine seeking. Personality traits, like reactivity to novelty, anxiety, and impulsivity, associated with increased risk for nicotine dependence in humans, are now also well characterized in rodents, providing the opportunity to study their role in nicotine seeking.
More recently, two promising studies support the notion that consistent individual differences in the reinforcing and incentive effects of nicotine can be observed. In an outbred strain of rats, Grebenstein et al (2015) reported individual variations in nicotine self-administration. Superficially, the nicotine reinforcement threshold and degree of compensation when decreasing nicotine dose were predicted by nicotine clearance, suggesting that nicotine seeking might be controlled by PF in some individuals, and less so in others, through biochemical differences affecting pharmacokinetics. Echoing the fast/slow metabolizer phenotypes in humans, the observations of Grebenstein et al (2015) offer interesting perspectives for studying the PF vs NPF balance in controlling nicotine seeking by identifying individual differences in nicotine metabolism.
In search for the mechanisms of individual vulnerability to cocaine or opioid addiction, sophisticated procedures have been developed to investigate psychobehavioral factors such as attribution of incentive salience to drug cues that might influence drug seeking. In the so-called sign trackers rats (STs), food- or drug- (cocaine, opioid) associated discrete cues are both more attractive (elicit approach) and more wanted (are conditioned reinforcers) than in goal trackers rats (GTs), in which presentation of reward-associated cues elicits approach to the location of reward delivery. For nicotine, Yager and Robinson (2015) showed that if STs rats want more a nicotine-associated cue, they approach a nicotine cue similarly to GTs, demonstrating nicotine-specific mechanisms of salience attribution. This model not only opens perspectives for the study of the mechanisms of salience attribution in general, but offers the opportunity to study the control of nicotine seeking by NPF and PF as a function of individual differences in salience attribution to nicotine cues.
Tobacco use is the net balance between factors promoting smoking maintenance (‘seeking mechanisms’) and factors promoting smoking cessation (‘motivation to stop’). Even if capturing motivation to stop is a challenge in animal models, they allow exploring mechanisms promoting nicotine seeking and taking.
Data support that individual variations in the mechanisms of nicotine seeking contribute to the heterogeneity of the population of tobacco smokers and may explain in part the limited efficacy of current therapeutic strategies for smoking cessation. Conditions are met to study these individual variations and identify their underlying neurobiological mechanisms using preclinical models in rodents. This strategy could increase our ability to develop individual-based therapeutic strategies for tobacco dependence.
FUNDING AND DISCLOSURE
The authors declare no conflict of interest.
Cohen A, George O (2013). Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking. Front Psychiatry 4: 41.
Falco AM, Bevins RA (2015). Individual differences in the behavioral effects of nicotine: a review of the preclinical animal literature. Pharmacol Biochem Behav 138: 80–90.
Falcone M, Cao W, Bernardo L, Tyndale RF, Loughead J, Lerman C (2016). Brain responses to smoking cues differ based on nicotine metabolism rate. Biol Psychiatry 80: 190–197.
Fowler CD, Kenny PJ (2014). Nicotine aversion: neurobiological mechanisms and relevance to tobacco dependence vulnerability. Neuropharmacology 76 Pt B: 533–544.
Grebenstein PE, Burroughs D, Roiko SA, Pentel PR, LeSage MG (2015). Predictors of the nicotine reinforcement threshold, compensation, and elasticity of demand in a rodent model of nicotine reduction policy. Drug Alcohol Depend 151: 181–193.
Hiroi N, Scott D (2009). Constitutional mechanisms of vulnerability and resilience to nicotine dependence. Mol Psychiatry 14: 653–667.
Hong LE, Hodgkinson CA, Yang Y, Sampath H, Ross TJ, Buchholz B et al (2010). A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad Sci USA 107: 13509–13514.
Janes AC, Smoller JW, David SP, Frederick BD, Haddad S, Basu A et al (2012). Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug Alcohol Depend 120: 7–13.
Mamoun M, Bergen AW, Shieh J, Wiggins A, Brody AL (2015). Biomarkers of response to smoking cessation pharmacotherapies: progress to date. CNS Drugs 29: 359–369.
Morel C, Fattore L, Pons S, Hay YA, Marti F, Lambolez B et al (2014). Nicotine consumption is regulated by a human polymorphism in dopamine neurons. Mol Psychiatry 19: 930–936.
Potvin S, Tikàsz A, LL Dinh-Williams, Bourque J, Mendrek A (2015). Cigarette cravings, impulsivity, and the brain. Front Psychiatry 6: 125.
Stoker AK, Markou A (2015). Neurobiological bases of cue- and nicotine-induced reinstatement of nicotine seeking: implications for the development of smoking cessation medications. Curr Top Behav Neurosci 24: 125–154.
Yager LM, Robinson TE (2015). Individual variation in the motivational properties of a nicotine cue: sign-trackers vs. goal-trackers. Psychopharmacology (Berl) 232: 3149–3160.
Wang T, Han W, Wang B, Jiang Q, Solberg-Woods LC, Palmer AA et al (2014). Propensity for social interaction predicts nicotine-reinforced behaviors in outbred rats. Genes Brain Behav 13: 202–212.
Research program of VD-G is supported by the FRM grant DPA20140629795, the EquipEx grant OptoPath (ANR-10-EQX-008-1), by INSERM, the University of Bordeaux, and the Aquitaine Region Council. VG-R is supported by an Inserm-Aquitaine Region Council fellowship (2015-1R30105). NC is supported by the FRM grant DPA20140629795.
About this article
Cite this article
Garcia-Rivas, V., Cannella, N. & Deroche-Gamonet, V. Individual Variations in the Mechanisms of Nicotine Seeking: A Key for Research on Nicotine Dependence. Neuropsychopharmacol 42, 584–586 (2017). https://doi.org/10.1038/npp.2016.176
Substance Use & Misuse (2021)
Addiction Biology (2019)
Varenicline Targets the Reinforcing-Enhancing Effect of Nicotine on Its Associated Salient Cue During Nicotine Self-administration in the Rat
Frontiers in Behavioral Neuroscience (2019)
An extended history of drug self-administration results in multiple sources of control over drug seeking behavior
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)